 |
Prospector
Profile
07.1196
|
| |
| DUSA Pharmaceuticals, Inc. |
NAICS |
325412 |
| 25 Upton Drive
Wilmington, MA 01887 |
Description |
Skin Care Products Mfg. |
| (978) 657-7500 |
Employees |
83 |
|
Revenue |
(mil) |
25.5820 |
| |
Income |
(mil) |
-31.3490 |
| |
Assets |
(mil) |
33.7550 |
| |
Liability |
(mil) |
7.4220 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
DUSA Pharmaceuticals, Inc. reported a net loss of $ $2,477,407 on revenues of $6,862,198 for the second quarter ended June 30, 2007, much lower than the net loss reported during the same quarter last year of $4,653,954 on revenues of $6,619,109. The Company also used cash for operating activities of $4,610,296 for the three months ended June 30, 2007, much lower than the net cash used of $6,632,270 during the same period last year. As a result of its recurring losses, the Company has an accumulated deficit of $126,735,309 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company owns or exclusively licenses patents and patent applications related to methods of using ALA and its unique physical forms in combination with light, compositions and apparatus for those methods, and unique physical forms of ALA. Effective September 29, 2003, the United States Patent and Trademark Office extended the term of U.S. Patent No. 5,079,262, with respect to the approved AK indication for Levulan®, until September 29, 2013. Under a license agreement with PARTEQ Research and Development Innovations, the Company holds an exclusive worldwide license to certain patent rights in the United States and a limited number of foreign countries. All United States patents and patent applications licensed from PARTEQ relating to ALA are method of treatment patents. The Company has patents and/or pending patent applications in the United States and in a number of foreign countries covering unique physical forms of ALA, compositions containing ALA, as well as ALA applicators, light sources for use with ALA, and other technology. It also owns patents covering Nicomide® and the AVAR® products, and has patent applications pending that will cover other products, including an application on the design of the applicator wand for ClindaReach™ pledgets. The Company has been issued more than 50 trademark registrations, and other applications are pending. [SEC Filing 10-K 03-16-07]
|
| |
|
Description:
The Company develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions.
|
| |
|
Officers:
D. Geoffrey Shulman (Chair & CEO); Jay M. Haft, Esq. (Vice Chair); Robert F. Doman (Pres. & COO); Richard C. Christopher (VP & CFO); John H. Abeles (Dir.); David Bartash (Dir.); Robert C. Lufkin (Dir.); Neal S. Penneys (Dir.); Magnus Moliteus (Dir.)
|
| |
|
Auditor:
Deloitte & Touche LLP
|
| |
|
Securities:
Common Stock-Symbol DUSA; NasdaqGM;
19,495,067 common shares outstanding as of August 6, 2007.
|
| |
| |
| |
| return to main page |
|
|
